{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:34:21Z","timestamp":1792683261913,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.05.019","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T21:33:45Z","timestamp":1622928825000},"page":"867.e1-867.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent\/Refractory Chronic Graft-Versus-Host Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Noriko","family":"Doki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2021.05.019_bib0001","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3324\/haematol.2011.049841","article-title":"The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality","volume":"96","author":"Pidala","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.019_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.beha.2008.02.010","article-title":"Prevention of chronic GVHD","volume":"21","author":"Lee","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.019_bib0003","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2021.05.019_bib0004","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.019_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/asheducation-2008.1.134","article-title":"Recognizing and managing chronic graft-versus-host disease","author":"Lee","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.019_bib0006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bmt.2013.151","article-title":"Risk factors and organ involvement of chronic GVHD in Japan","volume":"49","author":"Kanda","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.019_bib0007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbmt.2019.09.016","article-title":"A prospective, longitudinal observation of the incidence, treatment, and survival of late acute and chronic graft-versus-host disease by national institutes of health criteria in a japanese cohort","volume":"26","author":"Ohwada","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/01.moh.0000245689.47333.ff","article-title":"Chronic graft versus host disease","volume":"13","author":"Baird","year":"2006","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.019_bib0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOH.0000000000000026","article-title":"Graft-versus-host disease: why have we not made more progress?","volume":"21","author":"Jaglowski","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2021.05.019_bib0010","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","author":"Carreras","year":"2019"},{"key":"10.1016\/j.jtct.2021.05.019_bib0011","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hematopoietic Cell Transplantation (HCT): Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease. Version 2. 2020. 23 Mar 2020."},{"issue":"5","key":"10.1016\/j.jtct.2021.05.019_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17474086.2019.1605288","article-title":"A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease","volume":"12","author":"Csanadi","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.019_bib0013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2141.2010.08247.x","article-title":"Optimal management of chronic graft-versus-host disease in children","volume":"150","author":"Jacobsohn","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.019_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.019_bib0015","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jtct.2021.05.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.jtct.2021.05.019_bib0017","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jtct.2021.05.019_bib0018","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.05.019_bib0019","unstructured":"The Japan Society for Hematopoietic Cell Transplantation. Hematopoietic cell transplantation guideline GVHD (Version 4). Available at: http:\/\/www.jshct.com\/guideline\/pdf\/01_02_gvhd_ver04.pdf. Accessed March 1, 2021."},{"key":"10.1016\/j.jtct.2021.05.019_bib0020","unstructured":"Mallinckrodt receives approval in Japan of the CELLEX extracorporeal photopheresis system for treatment of chronic graft versus host disease. 2021. Available at: https:\/\/www.mallinckrodt.com\/about\/news-and-media\/news-detail\/?id=27116. Accessed April 28, 2021."},{"issue":"6","key":"10.1016\/j.jtct.2021.05.019_bib0021","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2021.05.019_bib0022","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report","volume":"21","author":"Carpenter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.019_bib0023","unstructured":"Pharmacyclics LLC. Imbruvica (ibrutinib) [package insert]. U.S. Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205552s017lbl.pdf. Accessed November 11, 2020."},{"issue":"4","key":"10.1016\/j.jtct.2021.05.019_bib0024","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.019_bib0025","unstructured":"FDA expands ibrutinib indications to chronic GVHD. 2017. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-ibrutinib-indications-chronic-gvhd. Accessed March 1, 2021."},{"issue":"8","key":"10.1016\/j.jtct.2021.05.019_bib0026","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2015.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report","volume":"21","author":"Martin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.019_bib0027","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2021.05.019_bib0028","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2019-129171","article-title":"Ibrutinib for chronic pulmonary graft-versus-host-disease after progression on prior therapy","volume":"134","author":"Singhal","year":"2019","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.jtct.2021.05.019_bib0029","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.HS9.0000564480.84127.74","article-title":"PS1556 Bruton tyrosine kinase inhibitor is an effective steroid-sparing agent in chronic graft-versus-host disease","volume":"3","author":"Ilhan","year":"2019","journal-title":"HemaSphere"},{"issue":"18","key":"10.1016\/j.jtct.2021.05.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019000386","article-title":"Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients","volume":"3","author":"Inamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"30","key":"10.1016\/j.jtct.2021.05.019_bib0031","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2012.42.3038","article-title":"Delivering care to long-term adult survivors of hematopoietic cell transplantation","volume":"30","author":"Syrjala","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.019_bib0032","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2021.05.019_bib0033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.019_bib0034","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1700806","article-title":"Quality of life following bone marrow transplantation: a comparison of patient reports with population norms","volume":"19","author":"Sutherland","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.019_bib0035","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease","volume":"23","author":"Kurosawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.019_bib0036","doi-asserted-by":"crossref","DOI":"10.1080\/17474086.2020.1818065","article-title":"Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review","volume":"13","author":"Csan\u00e1di","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"17","key":"10.1016\/j.jtct.2021.05.019_bib0037","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2021.05.019_bib0038","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2009.238","article-title":"Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)","volume":"45","author":"Mitchell","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.019_bib0039","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Sk","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2021.05.019_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.019_bib0041","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.019_bib0042","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.019_bib0043","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.019_bib44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:18Z","timestamp":1763003058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721009386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721009386"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent\/Refractory Chronic Graft-Versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}